Application of IL-21 to prepare immunosuppressor

An immunosuppressant, IL-21 technology, applied in the direction of blood/immune system cells, medical preparations containing active ingredients, animal cells, etc., can solve the problems of unclear IL-21B10 cells IL-10, and achieve application prospects wide range and high reliability

Inactive Publication Date: 2014-02-12
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, it is not clear whether IL-21 can promote the differentiation of B10 cells and the production of IL-10 at home and abroad, and there is no information about whether IL-21 plays an immune regulatory role by inducing the production of B10 and thus plays a role in autoimmune diseases such as SLE. therapeutic effect report

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of IL-21 to prepare immunosuppressor
  • Application of IL-21 to prepare immunosuppressor
  • Application of IL-21 to prepare immunosuppressor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1 In vitro IL-21 promotes the expression of IL-10mRNA in B10

[0040] Cultivate naive B lymphocytes in vitro, add 10ng / ml LPS and 10ng / ml IL-21 to the culture medium, culture for 5 hours or 24 hours, add 50ng / ml PMA and 500ng / mlionomycin and 20μg / ml brefeldin A; Real-time RT-PCR detection, the results are as follows figure 1 As shown, IL-21 can promote the expression of IL-10mRNA.

Embodiment 2

[0041] Example 2 In vitro IL-21 promotes B10 to secrete IL-10

[0042] Cultivate naive B lymphocytes, add 10ng / ml LPS and 10ng / ml IL-21 to the culture medium, culture for 48 hours, add 50ng / ml PMA and 500ng / ml ionomycin to the culture medium in the last 5 hours; ELISA detection, the result Such as figure 2 As shown, IL-21 can promote B10 to secrete IL-10.

Embodiment 3

[0043] Example 3 In vivo IL-21 is related to the secretion of IL-10

[0044] The inventors collected peripheral serum from 30 patients with systemic lupus erythematosus and 15 healthy controls, and detected the contents of IL-21 and IL-10 in peripheral blood by enzyme-linked adsorption assay, and found that the secretion of IL-21 was It is closely related to the secretion of IL-10 in the body; the inventors collected the MRL / lpr peripheral serum of 6 cases of spontaneous systemic lupus erythematosus mice at the age of 5 months and the peripheral serum of 6 cases of control B6 mice, and detected peripheral blood by ELISA The content of IL-21 and IL-10, through correlation analysis, the results show that the secretion of IL-21 is closely related to the secretion of IL-10 in vivo.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of immunosuppressive drugs, in particular to application of IL-21 to prepare an immunosuppressor and a method for promoting a regulatory B cell (B10) to differentiate and IL-10 to secrete by IL-21. Related experimental results show that: IL-21 is mainly used for promoting IL-10 to secrete by inducing phosphorylation-STAT3 to activate; IL-10 generated by induction can inhibit proliferation of in-vitro T cells and has the immunosuppressive action; and IL-21 can be used as the cell factor of in-vitro amplification cells and can be further used for preparing drugs for treating autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, scleroderma and the like.

Description

technical field [0001] The present invention relates to the field of immunosuppressive drugs, and relates to the use of IL-21 in the preparation of immunosuppressants. The IL-21 promotes the differentiation of regulatory B cells (B10 cells) and the secretion of IL-10 with immunosuppressive effects and further used for preparing medicines for treating systemic lupus erythematosus, rheumatoid arthritis, scleroderma and other autoimmune diseases. Background technique [0002] Autoimmune diseases are relatively common diseases that affect human health at present, often accompanied by damage to multiple organs and systems, and their pathogenesis is still unclear. In clinical practice, hormones and various immunosuppressants are often used for the treatment of autoimmune diseases. Commonly used drugs include; Long-term use can induce a series of side effects, such as long-term use of a large number of hormones can induce and aggravate coronary heart disease, diabetes, femoral hea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/20C12N5/0781A61P37/06
Inventor 杨雪邹和建
Owner AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap